Emerald Health Pharmaceuticals

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Emerald Health Pharmaceuticals (EHP) is a private clinical-stage biotech company with a portfolio of 25 novel, first-in-class new chemical entities (NCEs) covered by 20 issued patents, that can potentially modify and reverse disease progression in people suffering from neurodegenerative, inflammatory, autoimmune and fibrotic diseases with no cures and significant unmet medical needs. The company has two families of NCEs with unique multimodal mechanisms of action created through rational drug design to modulate specific receptors and biologic pathways in the body that are validated targets in many serious diseases. EHP has two lead product candidates in development, initially targeting 4 diseases: EHP-101 in Phase 2 for multiple sclerosis (MS) and system sclerosis (SSc), and EHP-102 in preclinical development for Parkinson's disease (PD) and Huntington's disease (HD). EHP has a highly experienced, expert management team, and globally recognized clinical and scientific advisors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
EHP-101 for multiple sclerosis and systemic sclerosis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President & Chief Executive Officer
Emerald Health Sciences